Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Sutro Biopharma, Inc is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 195 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $18.65 |
|---|---|
| 52-week range | $7.77 - $28.30 |
| 50-day moving average | $18.32 |
| 200-day moving average | $21.06 |
| Wall St. target price | $32.29 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.44 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.65 from 2021-06-08
| 1 week (2021-07-24) | N/A |
|---|---|
| 1 month (2021-07-02) | -0.96% |
| 3 months (2021-05-04) | -3.92% |
| 6 months (2021-01-31) | N/A |
| 1 year (2020-07-31) | N/A |
|---|---|
| 2 years (2019-07-31) | N/A |
| 3 years (2018-07-31) | N/A |
| 5 years (2016-07-31) | N/A |
| Revenue TTM | $50.2 million |
|---|---|
| Gross profit TTM | $-34,239,000 |
| Return on assets TTM | -17.27% |
| Return on equity TTM | -22.03% |
| Profit margin | -85.39% |
| Book value | $6.67 |
| Market capitalisation | $807.7 million |
TTM: trailing 12 months
There are currently 3.0 million Sutro Biopharma shares held short by investors – that's known as Sutro Biopharma's "short interest". This figure is 3.5% down from 3.1 million last month.
There are a few different ways that this level of interest in shorting Sutro Biopharma shares can be evaluated.
Sutro Biopharma's "short interest ratio" (SIR) is the quantity of Sutro Biopharma shares currently shorted divided by the average quantity of Sutro Biopharma shares traded daily (recently around 467212.93375394). Sutro Biopharma's SIR currently stands at 6.34. In other words for every 100,000 Sutro Biopharma shares traded daily on the market, roughly 6340 shares are currently held short.
However Sutro Biopharma's short interest can also be evaluated against the total number of Sutro Biopharma shares, or, against the total number of tradable Sutro Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sutro Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Sutro Biopharma shares in existence, roughly 60 shares are currently held short) or 0.0718% of the tradable shares (for every 100,000 tradable Sutro Biopharma shares, roughly 72 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sutro Biopharma.
Find out more about how you can short Sutro Biopharma stock.
We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $7.77 up to $28.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.7281. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
